News | May 29, 2024
Asahi Kasei to acquire Calliditas Therapeutics AB to accelerate growth
Asahi Kasei will offer to acquire all of the ordinary shares of Calliditas
Asahi Kasei will offer to acquire all of the ordinary shares of Calliditas
Dr. Reddy’s gets exclusive commercialization rights in the United States (U.S.) as well as semi-exclusive rights in Europe and United Kingdom (UK)
Sanofi will leverage this partnership to provide access to proprietary data to develop AI models
According to IQVIATM sales data for the 12-month period ending March 2024, the Combigan Ophthalmic Solution, 0.2%|0.5% market achieved annual sales of approximately $290.0 million
Annapurna will lead the company in India ensuring patient access to its highly innovative medicines and vaccines
The company has posted net profit of Rs. 59.16 crores for the Financial Year ended March 31, 2024
Collaboration to leverage AbbVie's psychiatry expertise and Gilgamesh's innovative research platform to develop next-generation neuroplastogens for the treatment of psychiatric disorders
Neuland Laboratories has reported total income of Rs. 390.36 crores during the period ended March 31, 2024
Investing in Malaysia's largest clinic operator to expand the healthcare business
First BTK inhibitor to show favourable trend in overall survival vs. standard-of-care chemoimmunotherapy in this setting
Subscribe To Our Newsletter & Stay Updated
